D. Lancaster

发表

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

G. Acton, A. Boddy, P. Kearns, 2017, Pediatric blood & cancer.

Tolerance of Nitrosurea-Based Multiagent Chemotherapy Regime for Low-Grade Pediatric Gliomas

D. Lancaster, J. Hoddes, A. Michalski, 2003, Journal of Neuro-Oncology.

Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations

N. Rahman, R. Scott, R. Nash, 2007, Journal of Medical Genetics.

Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.

M. Gaze, M. Partridge, F. Saran, 2007, Cancer biotherapy & radiopharmaceuticals.

Clinical profile and outcome of urotheliotropic viral haemorrhagic cystitis following haematopoietic stem cell transplantation: a 7-year tertiary centre analysis

G. Morgan, F. Davies, B. Shaw, 2011, Hematology.

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

P. Kearns, C. Zwaan, A. Place, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia

C. Stiller, K. Khabra, P. Anoop, 2012, Leukemia & lymphoma.

Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion

P. Kearns, J. Hancock, C. Harrison, 2020, British journal of haematology.

Intracranial hypertension in pediatric patients with acute lymphoblastic leukemia

P. Fallon, D. Lancaster, G. Vartzelis, 2009, Pediatric blood & cancer.

High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience.

M. Potter, K. Khabra, L. Moreno, 2019, Leukemia research.

Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.

E. Ball, A. Bashey, D. Lancaster, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

Comparison of Presentation and Outcome in 100 Pediatric Hodgkin Lymphoma Patients Treated at Children Hospital, Lahore, Pakistan and Royal Marsden Hospital, UK.

M. Faizan, D. Lancaster, Agha Shabbir Ali, 2016, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma

H. Mandeville, F. Saran, G. Flux, 2016, Nuclear medicine communications.

Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial

S. Love, A. Moorman, A. Roy, 2005, British journal of haematology.

Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia

R. Foà, P. Kearns, C. Zwaan, 2019, Clinical Cancer Research.

Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.

M. D. Den Boer, R. Pieters, A. Baruchel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toxicity and Outcome of Children and Adolescents Participating in Phase I/II Trials of Novel Anticancer Drugs: The Royal Marsden Experience

S. Zacharoulis, K. Pritchard-Jones, D. Hargrave, 2014, Journal of pediatric hematology/oncology.

Leukaemia survival trends in children with Down's syndrome in Great Britain, 1971–2000: a population-based study

M. Coleman, C. Stiller, D. Lancaster, 2009, Journal of Epidemiology & Community Health.

The role of immunotherapy in relapse/refractory precursor‐B acute lymphoblastic leukaemia: real‐life UK/Ireland experience in children and young adults

A. Vora, J. Moppett, P. Amrolia, 2020, British journal of haematology.

Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?

D. Lancaster, A. Atra, M. Champion, 2011, International journal of hematology.

Chronic hepatotoxicity following 6‐thioguanine therapy for childhood acute lymphoblastic leukaemia

K. Pritchard-Jones, S. Vaidya, D. Lancaster, 2004, British journal of haematology.

Defibrotide in the prevention and treatment of veno‐occlusive disease in autologous and allogeneic stem cell transplantation in children

A. Qureshi, L. Marshall, D. Lancaster, 2008, Pediatric blood & cancer.

RELAPSE OF PRIMITIVE MEDIASTINAL LYMPHOMA AS A MYELOID MASS FOLLOWING BEAM AUTOLOGOUS TRANSPLANT AND SUBSEQUENT REFRACTORINESS TO MATCHED UNRELATED UMBILICAL CORD BLOOD ALLOGRAFT

A. Wotherspoon, M. Potter, P. Anoop, 2009, Pediatric Hematology & Oncology.

Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia.

P. Kearns, R. Keenan, J. Vormoor, 2011, Journal of Clinical Oncology.

Dasatinib In Children and Adolescents with Relapsed or Refractory Leukemia: Results of the CA180018 Phase 1 Dose-Escalation Study of the Innovative Therapies for Children with Cancer (ITCC) Consortium

R. Pieters, A. Baruchel, M. L. Boer, 2010 .

Vocal Cord Palsy in Children With Cancer: A 10-Year Analysis of UK Pediatric Intensive Care Admissions

J. Bate, J. Round, D. Lancaster, 2017, Journal of pediatric hematology/oncology.

Dasatinib in Children and Adolescents with Relapsed or Refractory Leukemia: Interim Results of the CA180-018 Phase I Study from the ITCC Consortium.

R. Pieters, A. Baruchel, M. L. Boer, 2008 .

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

R. Gray, B. Warren, P. Quirke, 2012 .